<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CR</title>
	<atom:link href="http://www.stockbloghub.com/tag/cr/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Posts Positive Pixantrone Data</title>
		<link>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854</link>
		<comments>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76854</guid>
		<description><![CDATA[Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal. The study (n=28) tested the efficacy and safety of pixantrone as a combination therapy with fludarabine, dexamethasone and Biogen/Roche’s (BIIB/RHHBY) Rituxan (FPD-R) for the treatment of relapsed or refractory indolent non-hodgkin’s lymphoma (INHL). In this study pixantrone was substituted for mitoxantrone in the FPD-R regimen compared to the standard FND-R regimen. The data revealed that pixantrone in combination with fludarabine, dexamethasone and Rituxan was highly active in patients with relapsed or refractory INHL and produced complete response (CR) in 63% of patients. The overall response rate (ORR) was 89%. The response lasted for 40 months in the longest responding patient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HNAB) Hana Bioscience Encouraging Phase II Results</title>
		<link>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616</link>
		<comments>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616#comments</comments>
		<pubDate>Tue, 09 Nov 2010 18:28:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Hana Biosciences Inc]]></category>
		<category><![CDATA[HNAB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58616</guid>
		<description><![CDATA[Written by Grant Zeng, CFA Hana Biosciences Inc. ( HNAB ) A decent pipeline with late stage candidates&#8230; South San Francisco, CA based Hana Biosciences, Inc. (Hana) is a late development stage biopharmaceutical company which is focused on two cancer care areas: cancer therapeutics and cancer supportive care. The company’s lead cancer therapeutic candidate is Marqibo (vincristine sulfate liposome injection), a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine, for the treatment of relapsed/refractory adult acute lymphoblastic leukemia (ALL). Hana presented results from the registration-enabling Phase II clinical trial (rALLY) of Marqibo for ALL in June 2010 at the ASCO meeting. The data were compelling. Marqibo was administered as third-, fourth-, fifth-, and sixth-line single-agent therapy for ALL patients. The trial achieved 35% overall response rate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CR) Crane First Quarter Earnings Posted Ahead of Expectations</title>
		<link>http://www.stockbloghub.com/2010/04/21/cr-crane-first-quarter-earnings-posted-ahead-of-expectations/34555</link>
		<comments>http://www.stockbloghub.com/2010/04/21/cr-crane-first-quarter-earnings-posted-ahead-of-expectations/34555#comments</comments>
		<pubDate>Wed, 21 Apr 2010 21:45:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Conglomerates]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34555</guid>
		<description><![CDATA[Crane Co. (CR) posted first-quarter 2010 results after the closing bell on Monday. The company recorded a 43% growth in net income to $33.2 million from $23.3 million in the year-ago period. Earnings per share came in at 56 cents, which surpassed the Zacks Consensus Estimate by 6 cents and was primarily driven by management initiatives to control costs. During the quarter, Crane recorded a 4.5% decline in sales to $530.3 million, compared with $555.1 million in the year-ago quarter. The decrease was primarily attributable to an 8% decline in core sales (excluding the impact of currency, acquisitions and divestitures) partially offset by favorable currency translations. Segment Details Fluid Handling: Sales decreased 7% year-over-year to $247.8 million due to sluggish performance in later-cycle energy, chemical and pharmaceutical businesses reflecting continued ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/cr-crane-first-quarter-earnings-posted-ahead-of-expectations/34555/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review</title>
		<link>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187</link>
		<comments>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32187</guid>
		<description><![CDATA[Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CR) Crane Company Earnings Surprised by 25% in the Third Quarter</title>
		<link>http://www.stockbloghub.com/2009/11/01/cr-crane-company-earnings-surprised-by-25-in-the-third-quarter/19247</link>
		<comments>http://www.stockbloghub.com/2009/11/01/cr-crane-company-earnings-surprised-by-25-in-the-third-quarter/19247#comments</comments>
		<pubDate>Sun, 01 Nov 2009 23:14:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Conglomerates]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19247</guid>
		<description><![CDATA[Crane Company (CR) recently raised the bottom end of its full-year earnings guidance. The company has surprised on estimates 4 quarters in a row by an average of 24.22%. Crane is trading with a forward P/E of 14.42. Company Description Crane, which was founded in 1855, is a diversified manufacturer with 5 business segments and employees in 25 countries. The segments include: Aerospace &#38; Electronics which designs aircraft components including landing systems and electronics for military, medical and commercial applications including on Mars Rovers and fighter jets; Engineered Materials such as composites; Merchandising Systems like vending machines; Fluid Control Systems; and Controls. Crane Surprised by 25% in the Third Quarter On Oct 26, Crane reported third quarter results which easily beat the Zacks Consensus Estimate by 12 cents per share. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/cr-crane-company-earnings-surprised-by-25-in-the-third-quarter/19247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

